David Sigmund Liebeskind MD MD, FAAN, FAHA, FANA, FSVIN, FWSO
Neuroimaging, Vascular Neurology
UCLA Stroke Center
Join to view full profile
710 Westwood Plaza, C119 RNRCLos Angeles, CA 90095
Phone+1 310-794-6379
Fax+1 310-794-6379
Dr. Liebeskind is on Doximity
As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Summary
- Dr. David Liebeskind is a neurologist in Los Angeles, CA and is affiliated with multiple hospitals in the area, including Ronald Reagan UCLA Medical Center and UCLA Medical Center-Santa Monica. He received his medical degree from NYU School of Medicine and has been in practice 22 years. He also speaks multiple languages, including Spanish. He specializes in neuroimaging and vascular neurology and is experienced in general neurology, stroke, cerebrovascular disease, carotid disease, and neuroimaging.
Education & Training
UCLA David Geffen School of Medicine/UCLA Medical CenterResidency, Neurology, 1996 - 1999
Beth Israel Deaconess Medical CenterInternship, Internal Medicine, 1995 - 1996
New York University School of MedicineClass of 1995
Certifications & Licensure
CA State Medical License 1997 - 2027
PA State Medical License 1999 - 2004
NY State Medical License 1999 - 2002
American Board of Psychiatry and Neurology Neurology- American Board of Psychiatry and Neurology Vascular Neurology
Awards, Honors, & Recognition
- Regional Top Doctor Castle Connolly, 2021
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory 2014 Certified EHR Suite, Epic Systems Corporation, 2014, 2016-2017
- CMS Meaningful Use Stage 2 Certification EpicCare Ambulatory 2014 Certified EHR Suite, Epic Systems Corporation, 2014, 2016-2017
Clinical Trials
Publications & Presentations
PubMed
- Age Is an Effect Modifier of Thrombectomy Benefit in a Socioeconomically Vulnerable Stroke Population.Fabricio O Lima, Francisco José de A Mont'Alverne, Letícia C Rebello, Daniel G Abud, Gisele S Silva
Annals of Neurology. 2026-09-01 - Prehospital neuroprotectant in combination with post-arrival thrombolytic therapy for acute ischemic stroke. Secondary analysis of the FAST-MAG prehospital trial.Kristina Shkirkova, Sokena Zaidi, May A Kim-Tenser, Manuel Morales, Kristina Van De Goor
Journal of Stroke and Cerebrovascular Diseases. 2026-09-01 - MAD-MT Score: A Tool to Optimize Patient Selection for Mechanical Thrombectomy in Distal Vessel Occlusions.Huanwen Chen, Dhairya A Lakhani, Hamza Adel Salim, Marco Colasurdo, Vivek Yedavalli
Stroke. 2026-09-01
Journal Articles
- Thrombectomy 6 to 24 Hours After Stroke with a Mismatch Between Deficit and InfarctElad I. Levy, Qaisar A. Shah, Jawad F. Kirmani, Parita Bhuva, Cathy A. Sila, Michael G. Abraham, Amin Aghaebrahim, Wade S. Smith, Raul G. Nogueira, Brijesh P. Mehta, P..., The New England Journal of Medicine
Other
- Spontaneous cerebral and cervical artery dissection: Treatment and prognosisLiebeskind DS, Saver J
http://www.uptodate.com/contents/spontaneous-cerebral-and-cervical-artery-dissection-treatment-and-p
UpToDate, Wolters Kluwer Health - 2012-09-19 - Spontaneous cerebral and cervical artery dissection: Clinical features and diagnosisLiebeskind DS, Saver J
http://www.uptodate.com/contents/spontaneous-cerebral-and-cervical-artery-dissection-clinical-featur
UpToDate, Wolters Kluwer Health - 2013-01-02
Authored Content
- Thrombectomy 6 to 24 Hours After Stroke with a Mismatch Between Deficit and InfarctNovember 2017
- Thrombectomy 6 to 24 Hours After Stroke with a Mismatch Between Deficit and InfarctNovember 2017
- Thrombectomy 6 to 24 Hours After Stroke with a Mismatch Between Deficit and InfarctNovember 2017
Press Mentions
Middle Meningeal Artery Embolization in the Treatment of Chronic HeadachesJune 20th, 2025- Stroke Patients Discharged from Hospital Sooner When Administered Revalesio's RNS60; New Statistically Significant Finding from Revalesio's Phase 2 Clinical TrialApril 9th, 2025
- GNT Pharma Reports Significant Improvements in Stroke Patients Treated with Its Pioneering Phase 3 Drug Nelonemdaz™December 11th, 2024
Grant Support
- CAPTIVA-MRIYALE UNIVERSITY2023–2030
- Shear Stress and Endothelial Pathophysiology in Intracranial AtherosclerosisUNIVERSITY OF SOUTHERN CALIFORNIA2020–2030
- Platelet Expression of FcgammaRIIa and Arterial Hemodynamics to Predict Recurrent Stroke in Intracranial AtherosclerosisUNIVERSITY OF SOUTHERN CALIFORNIA2026–2027
- Carotid Revascularization and Medical Management for Asymptomatic CarotidStenosis Trial - Hemodynamics (CREST-H)COLUMBIA UNIVERSITY HEALTH SCIENCES2017–2027
- CAPTIVA-MRIYALE UNIVERSITY2023–2024
Professional Memberships
- Society of Vascular and Interventional Neurology (SVIN)President
- American Society of Neuroimaging (ASN)Past-President
Other Languages
- Spanish
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
